Published in J Biol Chem on July 08, 2010
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
Emerging vaccine informatics. J Biomed Biotechnol (2011) 1.12
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. Mol Cell Proteomics (2015) 1.05
MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles. J Immunol Methods (2010) 0.98
The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J (2012) 0.91
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother (2013) 0.90
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res (2015) 0.89
TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci U S A (2015) 0.87
Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front Immunol (2011) 0.86
Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85
HPVdb: a data mining system for knowledge discovery in human papillomavirus with applications in T cell immunology and vaccinology. Database (Oxford) (2014) 0.84
Conservation analysis of dengue virus T-cell epitope-based vaccine candidates using Peptide block entropy. Front Immunol (2011) 0.81
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy. Cancer Immunol Res (2015) 0.78
Forward Vaccinology: CTL Targeting Based upon Physical Detection of HLA-Bound Peptides. Front Immunol (2014) 0.77
Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma. Br J Haematol (2013) 0.77
Big data analytics in immunology: a knowledge-based approach. Biomed Res Int (2014) 0.75
The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res (2016) 0.75
Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses. J Virol (2016) 0.75
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science (1992) 8.68
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol (1977) 5.21
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics (1999) 4.88
Mechanisms of human papillomavirus-induced oncogenesis. J Virol (2004) 3.95
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73
NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59
Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev (2004) 3.52
More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov (2007) 2.68
Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
Immune responses to human papillomavirus. Vaccine (2006) 2.37
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol (2008) 2.30
Tumor antigens recognized by T cells. Immunol Today (1997) 2.28
The IMGT/HLA database. Nucleic Acids Res (2008) 2.22
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. Science (1977) 2.00
Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer (2002) 1.92
Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature (1992) 1.83
Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol (2004) 1.81
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today (1996) 1.79
Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature (1992) 1.76
Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens (2005) 1.61
Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J Virol (1997) 1.59
HPV: from infection to cancer. Biochem Soc Trans (2007) 1.47
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J Biol Chem (2003) 1.38
Progress on new vaccine strategies against chronic viral infections. J Clin Invest (2004) 1.38
A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res (2000) 1.32
Vaccinology in the genome era. J Clin Invest (2009) 1.31
Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets (2007) 1.26
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (2001) 1.25
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer (2006) 1.18
HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol (2006) 1.15
Propagation of infectious human papillomavirus type 16 by using an adenovirus and Cre/LoxP mechanism. Proc Natl Acad Sci U S A (2004) 1.15
Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol (2004) 1.14
Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst (1997) 1.13
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 1.11
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer (2008) 1.11
Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes. J Virol (2005) 1.10
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother (2000) 1.09
Structural basis of T cell recognition of peptides bound to MHC molecules. Mol Immunol (2002) 1.08
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther (2006) 1.08
Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res (2004) 1.05
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother (2004) 1.04
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol (2007) 1.03
Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res (1998) 1.03
The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology (2003) 1.02
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med (2003) 1.01
Crystal structures of murine MHC Class I H-2 D(b) and K(b) molecules in complex with CTL epitopes from influenza A virus: implications for TCR repertoire selection and immunodominance. J Mol Biol (2004) 1.00
Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene (2000) 0.98
The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol (2002) 0.98
From genome to vaccine--new immunoinformatics tools for vaccine design. Methods (2004) 0.97
Distribution of HLA-A, -B, -Cw, and -DRB1 alleles and haplotypes in an isolated Han population in Southwest China. Tissue Antigens (2009) 0.97
Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol (2000) 0.97
Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol (2007) 0.97
Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother Emphasis Tumor Immunol (1993) 0.93
Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther (2007) 0.93
Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens (2000) 0.93
Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res (2002) 0.93
Moving forward: human papillomavirus vaccination and the prevention of cervical cancer. J Womens Health (Larchmt) (2007) 0.92
Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol Oncol (2005) 0.90
MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs (2007) 0.89
Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res (2001) 0.88
Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1--E4 protein and provides a molecular basis for its accumulation. J Virol (2008) 0.88
Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res (2004) 0.87
Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope. Int J Cancer (2007) 0.86
Information technologies for vaccine research. Expert Rev Vaccines (2005) 0.86
A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS (2006) 0.85
HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol (2005) 0.85
Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. Int J Cancer (2005) 0.85
HPV16 E1--E4 protein is phosphorylated by Cdk2/cyclin A and relocalizes this complex to the cytoplasm. Virology (2006) 0.85
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. Int J Cancer (2008) 0.85
HPV vaccines: the beginning of the end for cervical cancer. Curr Opin Immunol (2007) 0.82
Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. Int J Cancer (2003) 0.78
Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions. J Med Virol (2009) 0.77
[Analysis on haplotypes of five HLA loci in southern Chinese Han population by sequence-based typing]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2009) 0.77
Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer. Int J Oncol (2005) 0.76
CancerScope: FDA Advisory Committee supports second HPV vaccine. Cancer (2009) 0.76
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell (2011) 3.31
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity (2008) 3.01
Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics (2004) 2.49
Prediction of MHC class I binding peptides using profile motifs. Hum Immunol (2002) 2.43
The alphabeta T cell receptor is an anisotropic mechanosensor. J Biol Chem (2009) 2.41
Reverse transcriptase template switching and false alternative transcripts. Genomics (2006) 2.38
Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol (2008) 2.30
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30
Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell (2006) 2.21
Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics (2008) 2.17
Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002) 2.14
MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res (2005) 2.05
Developmental bias in cleavage-stage mouse blastomeres. Curr Biol (2012) 1.98
Exchange of DNA base pairs that coincides with recognition of homology promoted by E. coli RecA protein. Mol Cell (2004) 1.95
Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms. J Mol Biol (2003) 1.88
Complete-proteome mapping of human influenza A adaptive mutations: implications for human transmissibility of zoonotic strains. PLoS One (2010) 1.87
A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol (2008) 1.86
Dragon Promoter Finder: recognition of vertebrate RNA polymerase II promoters. Bioinformatics (2002) 1.85
Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci U S A (2009) 1.79
Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One (2007) 1.72
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol (2002) 1.69
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem (2011) 1.68
Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by large-scale mutual information analysis. BMC Bioinformatics (2008) 1.61
Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol Med (2002) 1.61
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.58
CD8 alpha alpha homodimer expression and role in CD8 T cell memory generation during influenza virus A infection in mice. Eur J Immunol (2005) 1.56
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest (2005) 1.50
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol (2015) 1.47
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses (2005) 1.44
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother (2007) 1.43
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. J Am Chem Soc (2008) 1.39
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.38
Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J Biol Chem (2003) 1.38
FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Am Chem Soc (2006) 1.36
Solution structure of the CD3epsilondelta ectodomain and comparison with CD3epsilongamma as a basis for modeling T cell receptor topology and signaling. Proc Natl Acad Sci U S A (2004) 1.33
Prediction of promiscuous peptides that bind HLA class I molecules. Immunol Cell Biol (2002) 1.33
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry (2003) 1.32
Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. J Biosci Bioeng (2002) 1.31
A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol (2007) 1.30
PVS: a web server for protein sequence variability analysis tuned to facilitate conserved epitope discovery. Nucleic Acids Res (2008) 1.30
The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal (2009) 1.29
Sialic acid capping of CD8beta core 1-O-glycans controls thymocyte-major histocompatibility complex class I interaction. J Biol Chem (2002) 1.29
Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol (2011) 1.29
Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent. Antimicrob Agents Chemother (2002) 1.28
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother (2004) 1.27
PlexinD1 glycoprotein controls migration of positively selected thymocytes into the medulla. Immunity (2008) 1.27
Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J Virol (2009) 1.27
The crystal structure of a TL/CD8alphaalpha complex at 2.1 A resolution: implications for modulation of T cell activation and memory. Immunity (2003) 1.25
Information for the Coordinates of Exons (ICE): a human splice sites database. Genomics (2004) 1.24
Transcriptionally abundant major histocompatibility complex class I alleles are fundamental to nonhuman primate simian immunodeficiency virus-specific CD8+ T cell responses. J Virol (2011) 1.24
Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis (2008) 1.23
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J Biol Chem (2004) 1.21
The structural basis of αβ T-lineage immune recognition: TCR docking topologies, mechanotransduction, and co-receptor function. Immunol Rev (2012) 1.20
PREDBALB/c: a system for the prediction of peptide binding to H2d molecules, a haplotype of the BALB/c mouse. Nucleic Acids Res (2005) 1.20
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Brief Bioinform (2009) 1.19
Supporting the curation of biological databases with reusable text mining. Genome Inform (2005) 1.18
Machine learning competition in immunology - Prediction of HLA class I binding peptides. J Immunol Methods (2011) 1.18
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci (2007) 1.16
Prediction of methylated CpGs in DNA sequences using a support vector machine. FEBS Lett (2005) 1.16
Prediction of peptide-MHC binding using profiles. Methods Mol Biol (2007) 1.16
ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Philos Trans A Math Phys Eng Sci (2010) 1.16
From docking false-positive to active anti-HIV agent. J Med Chem (2007) 1.16
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol (2005) 1.15
An antibody-recruiting small molecule that targets HIV gp120. J Am Chem Soc (2009) 1.15
Computer model for recognition of functional transcription start sites in RNA polymerase II promoters of vertebrates. J Mol Graph Model (2003) 1.15
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.15
SCORPION2: a database for structure-function analysis of scorpion toxins. Toxicon (2006) 1.14
EPIMHC: a curated database of MHC-binding peptides for customized computational vaccinology. Bioinformatics (2005) 1.14
PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res (2005) 1.14
Combining cellular automata and Lattice Boltzmann method to model multiscale avascular tumor growth coupled with nutrient diffusion and immune competition. J Immunol Methods (2011) 1.14
Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem (2002) 1.13
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res (2002) 1.13
Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS (2013) 1.13
Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine (2006) 1.12
Ultra-high resolution HLA genotyping and allele discovery by highly multiplexed cDNA amplicon pyrosequencing. BMC Genomics (2012) 1.12
Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J Biol Chem (2004) 1.11
CysView: protein classification based on cysteine pairing patterns. Nucleic Acids Res (2004) 1.10
Prediction of HLA-DQ3.2beta ligands: evidence of multiple registers in class II binding peptides. Bioinformatics (2006) 1.10
Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation. Protein Sci (2013) 1.10
Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials (2011) 1.10
Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J Am Chem Soc (2011) 1.10
Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J Immunol Methods (2009) 1.10
Definition of MHC supertypes through clustering of MHC peptide-binding repertoires. Methods Mol Biol (2007) 1.09
Nonconserved residues Ala287 and Ser290 of the Cryptosporidium hominis thymidylate synthase domain facilitate its rapid rate of catalysis. Biochemistry (2007) 1.09